Onivyde: Getting-to know about Life-Saving treatment for Metastatic Pancreatic Cancer
As we all know that we are in the last month of the life-changing year and are desperately waiting for getting the shot of COVID vaccine and making ourselves immune against the deadly virus and getting the things back to normal. But there are some people who are battling for their lives and fighting bravely with different types of cancer. One such type of cancer is the pancreatic cancer. Pancreatic cancer refers to the abnormal growth of malignant cells in the tissues of the pancreas that gradually replace all the healthy tissues. As it is difficult to detect the cancer in the pancreas, it is often diagnosed at more advanced stages.
In our previous blog, we discovered a lot about pancreatic cancer. From watching out for the symptoms, we shared the causes and steps for preventing the pancreatic cancer. Now, we will get to know about the life-saving treatment for the patients fighting with pancreatic cancer.
Exploring out the Life-Saving Drug: Onivyde (Irinotecan Liposome Injection)
Onivyde (irinotecan Liposome Injection) is a topoisomerase inhibitor. The United States Food and Drug Administration approved Onivyde (Irinotecan Liposome Injection) in a fast track status to be used in combination with fluorouracil and leucovorin for patients with advanced pancreatic cancer.
Onivyde (irinotecan liposome injection) is a topoisomerase inhibitor encapsulated in a lipid bilayer vesicle or liposome. Topoisomerase 1 relives torsional strain in DNA by inducing single-strand breaks. For the patients whose disease has progressed following gemcitabine treatment, irinotecan liposome injection (ONIVYDE) in combination with Fluorouracil (5-FU) and Leucovorin (LV) has proved to help patients live longer. It is the only first and second-line treatment approved by the Federal Drug Administration in combination with 5-FU/LV for metastatic pancreatic cancer after gemcitabine-based therapy.
Taking the Treatment
As ONIVYDE is a cytotoxic drug, it should be handled carefully. Dilute the calculated volume of ONIVYDE in 500 mL 5% Dextrose Injection and mix them gently. Protect the diluted solution from the light. The diluted solution should be stored under refrigerated conditions (2 degree Celsius to 8 degree Celsius). Allow diluted solution to come to room temperature prior to utilisation.
Onivyde is given as an injection for intravenous infusion. The team of doctors will have to monitor the side effect of Onivyde before giving Leucovorin and fluorouracil. The recommended dose of Onivyde is 70 mg/m2 which should be monitored by intravenous infusion over 90 minutes every 2 week. After analysing the side effects, the doctors will increase the dosage to 70 mg/m2 in subsequent cycles.
Handling out the side effects
There is a possibility of the occurrence of many side effects together if you are taking the treatment. It is better if you keep some emergency medical help ready, otherwise, the situation can get out of control. Following are the side effects of Onivyde (irinotecan Liposome Injection):
- Diarrhea, Fatigue, Vomiting
- Nausea, Decreased Appetite, Stomatitis
- Pyrexia, Lymphopenia, Neutropenia
For more information on pancreatic cancer-related issues, schedule an appointment for a consultation with the best doctor for the treatment. You can also reach out to the advisors at Indian Pharma Network as they will guide you through the treatment and will help you arrange the medicines for the treatments.
Reach out to the best pharmaceutical consultants in the industry at Indian Pharma Network, New Delhi. As the ONIVYDE requires a certain amount of refrigerated cold temperature, the experts at Indian Pharma Network, New Delhi will help you to provide the treatment and medication from international borders. It helps you in connecting you with the best doctors available at the national or international level.
Head on to: https://indianpharmanetwork.co.in/
Or
Call Mr Neeraj Nagpal on 9811747774
References:
- https://www.centerwatch.com/directories/1067-fda-approved-drugs/listing/3945-onivyde-irinotecan-liposome-injection
- https://reference.medscape.com/drug/onivyde-irinotecan-liposomal-1000044#3
- https://www.onivyde.com/hcp/
- https://www.businesswire.com/news/home/20200616005954/en/Ipsen-Receives-FDA-Fast-Track-Designation-for-Liposomal-Irinotecan-ONIVYDE%C2%AE-as-a-First-Line-Combination-Treatment-for-Metastatic-Pancreatic-Cancer
- https://www.onivyde.com/hcp/treatment-information/how-onivyde-works/
